Compounds isolated from rattlesnake venom show activity against hepatitis C virus

February 9, 2018, FAPESP
Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Credit: Center for the Study of Hepatitis C, The Rockefeller University.

A group of Brazilian scientists has achieved promising results using isolated compounds from the venom of the South American rattlesnake to combat hepatitis C. The investigation was based on records in scientific literature in which animal venom showed activity against some viruses, such as yellow fever, measles and dengue, which belongs to the same Flaviviridae virus family as hepatitis.

There is a great need for new methods in the fight C. The therapies available are expensive, have adverse side effects, and entail viral resistance. In Sao Paulo State, Brazil, some 50 percent of liver transplants are performed on hepatitis B or C patients, according to the state's health department. Hepatitis C patients alone account for 40 percent of all liver transplants in São Paulo.

The researchers tested three from the venom of Crotalus durissus terrificus rattlesnake, and also investigated the antiviral potential of flavonoids extracted from Pterogyne nitens, a kind of plant endemic to Brazil. Results from these experiments were published in PloS One and Scientific Reports, respectively.

In the Laboratory of Toxicology at FCF-USP, two proteins from the rattlesnake venom were successfully isolated: phospholipase A2 (PLA2-CB) and crotapotin (CP). They are found in nature as subunits of the crotoxin protein complex, which the researchers also tested.

In a series of in vitro experiments with cultured , they tested the antiviral action of the two compounds, both separately and together in the protein complex. They observed the compounds' effects on human (to prevent infection by the ) and directly on hepatitis C virus.

The hepatitis C virus genome consists of a single strand of RNA (ribonucleic acid), which is a simple chain of nucleotides encoding the proteins in the virus. "This virus invades the human host cell to replicate, producing new viral particles. Inside the host cell, the virus produces a complementary strand of RNA, from which molecules of viral genome will emerge to constitute the new particles," said Ana Carolina Gomes Jardim, head of the Virology Laboratory in ICBIM-UFU.

"Our research showed that phospholipase can intercalate into double-stranded RNA, a virus replication intermediate, inhibiting the production of new viral particles. Intercalation reduced these by 86 percent compared with their production in the absence of phospholipase." When the same experiment was performed using crotoxin, production of viral particles fell 58 percent.

The second stage of the research consisted of verifying whether the compounds blocked the virus's entry into cultured human cells. In this case, the results were even more satisfactory: Phospholipase blocked 97 percent of viral cell entry, and crotoxin reduced viral infection by 85 percent.

Lastly, they tested crotapotin, another compound isolated from the same rattlesnake's venom. Crotapotin had no inhibitory effect on viral entry or replication, but did affect another stage of the virus's life cycle, reducing the release of new viral particles from cells by 78 percent. Treatment with crotoxin achieved 50 percent inhibition of viral release.

According to the researchers, the results of the experiments show that phospholipase and crotapotin produced better results when used separately than together.

Brazilian flora

The second article on the action of chemical compounds against hepatitis C virus describes substances derived from Brazilian flora: sorbifolin and pedalitin, both flavonoids isolated from the leaves of Pterogyne nitens during the experiments conducted by Professor Luis Octávio Regasini at UNESP's Green & Medicinal Chemistry Laboratory in Sao José do Rio Preto.

Flavonoids are compounds found in fruit, flowers, vegetables, honey and wine. As with the compounds isolated from rattlesnake venom, the flavonoids were tested for antiviral action in human cells infected with hepatitis C virus and in uninfected cells. "Sorbifolin blocked viral entry into human cells in 45 percent of cases, while pedalitin provided more promising results, blocking entry in 79 percent of cases. The experiment was performed with two genotypes of hepatitis C virus: genotype 2A, the standard type in all studies, and genotype 3, the second most prevalent in Brazil. In both cases, the antiviral action of the flavonoids was equivalent," Gomes Jardim said.

At the other end of the viral life cycle, the flavonoids had no effect on viral particle replication and did not prevent their release from infected cells.

"The flavonoids from P. nitens are among some 200 tested compounds isolated from Brazilian plants or synthesized using natural structures by Professor Regasini," said Paula Rahal, who coordinates the Virology Group at the Genomic Studies Laboratory at IBILCE-UNESP. "These two flavonoids were tested against hepatitis C virus because they'd been shown to have antiviral action in experiments with dengue virus."

Explore further: Ebola virus exploits host enzyme for efficient entry to target cells

More information: Jacqueline Farinha Shimizu et al, Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle, PLOS ONE (2017). DOI: 10.1371/journal.pone.0187857

Related Stories

Ebola virus exploits host enzyme for efficient entry to target cells

February 7, 2018
Researchers have identified a key process that enables the deadly Ebola virus to infect host cells, providing a novel target for developing antiviral drugs. The Ebola virus incorporates a cellular enzyme into its virus particles, ...

Hepatitis C virus: How viral proteins interact in human cells

May 8, 2014
Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms ...

Natural immunity may lead fight against liver disease

October 27, 2015
University of Adelaide researchers have uncovered the role played by a family of genes, which can suppress hepatitis C virus (HCV) infection within the liver.

New compounds show promise against hepatitis C infection

April 12, 2011
Two bioflavonoids, catechin and naringenin, have displayed antiviral activity on tissue culture infected with Hepatitis C.

Study builds understanding of hepatitis C virus replication

February 23, 2015
Hepatitis C virus infection is a common cause of liver disease and of liver cancer in the United States. Through a new study that explores one aspect of how the virus hijacks host cell machinery to replicate itself, UNC Lineberger ...

Recommended for you

Lung-on-a-chip simulates pulmonary fibrosis

May 25, 2018
Developing new medicines to treat pulmonary fibrosis, one of the most common and serious forms of lung disease, is not easy.

Reconstructing Zika's spread

May 24, 2018
The urgent threat from Zika virus, which dominated news headlines in the spring and summer of 2016, has passed for now. But research into how Zika and other mosquito-borne infections spread and cause epidemics is still very ...

Tick bite protection: New CDC study adds to the promise of permethrin-treated clothing

May 24, 2018
The case for permethrin-treated clothing to prevent tick bites keeps getting stronger.

Molecular network boosts drug resistance and virulence in hospital-acquired bacterium

May 24, 2018
In response to antibiotics, a gene regulation network found in the bacterium Acinetobacter baumannii acts to boost both virulence and antibiotic resistance. Edward Geisinger of Tufts University School of Medicine and colleagues ...

Past use of disinfectants and PPE for Ebola could inform future outbreaks

May 24, 2018
Data from the 2014 Ebola virus outbreak at two Sierra Leone facilities reveal daily usage rates for disinfectant and personal protective equipment, informing future outbreaks, according to a study published May 24, 2018 in ...

Early lactate measurements appear to improve results for septic patients

May 24, 2018
On October 1, 2015, the United States Centers for Medicare and Medicaid Services (CMS) issued a bundle of recommendations defining optimal treatment of patients suffering from sepsis, a life-threatening response to infection ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.